ArticleFrontiers in immunology2026
Efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell in the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To retrospectively analyze the efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell (CD19 CAR T-cell) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Methods: Thirty-six R/R DLBCL patients who received zanubrutinib and camrelizumab combined with CD19 CAR T-cell from January 2022 to June 2024 were selected in the combined group. Twenty R/R DLBCL patients who received only CD19 CART-cell were included in the non-combined group. The efficacy and safety of these two groups were observed and compared. Results: (1) The complete-response (CR) rates of the combined group after 1, 3, and 6 months were 61%, 75%, and 81%, respectively, while those of the non-combined group were 60%, 65%, and 60%, respectively. There were differences in CR rates at months 3 and 6 between the two groups ( Conclusions: Zanubrutinib and camrelizumab may enhance the efficacy of CAR T-cell therapy in R/R DLBCL with a manageable safety. The combined therapy prolongs the expansion time of CAR T-cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.